
Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals
J. Virol. Li et al.
83: 1045
Supplemental material
Files in this Data Supplement:
- Supplemental file 1
-
Table S1 (gp120 (YU2) variable region-derived peptides used as competitor in the inhibition of neutralization assay.)
Table S2 (gp41 peptides used as competitor in the inhibition of neutralization assay.)
Zipped PDF file, 30K.
- Supplemental file 2
-
Fig. S1 (HIV-1 envelope glycoprotein neutrallization surfaces and gp120 adsorption process.)
Zipped TIF file, 1.2MB.
- Supplemental file 3
-
Fig. S2 (Potency and breadth of neutralization by selected HIV+ sera.)
Zipped EPS file, 376K.
- Supplemental file 4
-
Fig. S3 (Verification of protein coupling, structural integrity of coupled gp120, and efficiency of antibody adsorption.)
Zipped EPS file, 980K.
- Supplemental file 5
-
Fig. S4 (CD4bs antibody specificity of serum.)
Zipped EPS file, 245K.
- Supplemental file 6
-
Fig. S5 (gp1201420R mutant protein selectively eliminates binding of monoclonal antibodies directed toward the coreceptor binding regions.)
Zipped EPS file, 195K.
- Supplemental file 7
-
Fig. S6 (Levels of MPER-binding antibodies in the HIV+ sera detected by ELISA.)
Zipped EPS file, 241K.